The publication of this infographic was supported by Castle Biosciences.
This content is intended for US Healthcare Professionals.
This infographic explores how genomic testing, specifically the 31-GEP test, can enhance melanoma management by providing personalized risk assessments that inform clinical decision-making. It highlights how this test can improve patient outcomes through targeted care strategies.
Key Insights:
- Understand the personalized melanoma risk assessment provided by the 31-GEP test and its role in clinical decision-making.
- Learn how the test aids in decisions regarding sentinel lymph node biopsies (SLNB) and identifies patients who may benefit from early intervention.
- Explore how the 31-GEP test supports earlier detection of melanoma recurrence and improves survival rates.
